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Sustained hematopoiesis after double-unit cord blood transplantation (dCBT) is mediated by 1 unit in nearly
all patients. To investigate the associations between nondominant unit characteristics and neutrophil
engraftment, we studied 129 consecutive myeloablative dCBT recipients. Ninety-ﬁve percent (95% conﬁdence
interval, 90 to 98) of patients engrafted. Detection of the nondominant unit 21 to 28 days after dCBT was not
associated with improved neutrophil engraftment. In univariate analyses, nondominant unit characteristics
(infused total nucleated cell [TNC] and viable CD3þ cell doses) were signiﬁcantly associated with speed and
success of neutrophil engraftment as were dominant unit characteristics (infused TNC; viable CD34þ, viable
CD3þ, and viable CD3-56þ16þ cell doses; and post-thaw CD34þ cell viability). In multivariate analysis, higher
infused TNC dose of the nondominant unit was independently associated with improved neutrophil
engraftment, even when this unit did not contribute to donor hematopoiesis. In further subgroup analysis,
this association was only evident when the infused viable CD34þ cell dose of the dominant unit was low
(<1.20  105/kg). These ﬁndings suggest nondominant units mediate a dose-dependent facilitation of
engraftment in myeloablative dCBT and support continued investigation of dCBT biology and the clinical
practice of dCBT in adults in whom low cell dose grafts are common.
 2015 American Society for Blood and Marrow Transplantation.INTRODUCTION overall utility of dCBT. However, adult dCBT with 2 units of
Double-unit cord blood (dCB) grafts have been used as a
strategy to augment engraftment in patients without a single
unit with an adequate total nucleated cell (TNC) dose [1]. In
most patients, however, only 1 unit engrafts and the other
unit is undetectable by 3 to 4 weeks after transplantation
[1-3]. Even as early as 7 days post-transplant, unit domi-
nance may already be apparent in chimerism testing [4,5].
Additionally, a randomized trial in pediatric myeloablative
single-unit or dCB transplantation (dCBT) with adequately
dosed units (Bone Marrow Transplant Clinical Trials Network
[BMT CTN] 0501) [6] found difference in neutrophil
engraftment between single and double-unit transplants.
These ﬁndings have led many investigators to question thedgments on page 1984.
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ty for Blood and Marrow Transplantation.very low TNC dose has been associated with neutrophil
engraftment rates comparable with that of adequately dosed
(deﬁned as pre-cryopreservation TNC dose  2.5  107/kg)
single-unit CBT [7-10]. This observation suggests that when
cell dose is limited, the nonengrafting unit may facilitate
engraftment of the dominant unit.
Assessment of dCBT experience has been hindered by
many series having only reported the combined cell dose of
both units without evaluating the contribution of each unit
to engraftment [7-10]. We have previously documented that
the percentage of viable CD34þ cells postthaw is a critical
determinant of unit engraftment potential [2,11] and that the
infused viable CD34þ cell dose of the dominant unit is the
most important determinant of neutrophil engraftment after
myeloablative dCBT [12]. Here, we evaluated the potential
contribution of the nondominant unit to neutrophil
engraftment by examining the effects, if any, of detecting
both units post-transplantation as well as the association
between neutrophil engraftment and the characteristics of
D. Purtill et al. / Biol Blood Marrow Transplant 21 (2015) 1981e19841982the nondominant unit. Our hypothesis was that higher
nondominant unit cell dosewill be associatedwith improved
engraftment of the dominant unit.METHODS
Patients and Graft Characteristics
During the study period all patients with hematologic malignancies
undergoing CBT received double-unit grafts. Consecutive patients who un-
derwentmyeloablative dCBTas their ﬁrst allograft for the treatment of acute
leukemia in morphologic remission or aplasia, myelodysplastic syndrome,
myeloproliferative neoplasms, or high-risk lymphoid malignancies between
October 2005 and August 2013 were eligible (n ¼ 130) for analysis. One
patient who died 19 days post-transplant without chimerism assessment
was excluded, leaving 129 patients for engraftment analysis. This patient
cohort has previously been described in a study of the association between
engraftment and dominant unit characteristics and determinants of unit
quality [12].
All study patients signed informed consent for the analysis of dCBT
outcomes. Permission to use clinical and laboratory information was ob-
tained from the Memorial Sloan Kettering Cancer Center Institutional Re-
view/Privacy Board. Myeloablative conditioning consisted predominantly of
ﬂudarabine and total body irradiation as previously reported [12-15],
although a small number of children received only chemotherapy-based
preparative regimens. A calcineurin-inhibitor and mycophenolate mofetil
were used for graft-versus-host disease prophylaxis, and no patient received
antithymocyte globulin [13,14]. Granulocyte colony-stimulating factor (5 mg/
kg/day rounded to vial size) was given from post-transplant day 7 to pro-
mote neutrophil recovery.CB Unit Characteristics
Per programmatic policy, all CB units in this analysis (n ¼ 258) were
4-6/6 HLA-A, -B antigen, -DRB1 allele matched to the recipient and had a
cryopreserved TNC  1.5  107/kg [12]. Units underwent high-resolution
typing for HLA-A, -B, -C, and -DRB1, permitting analysis of
donorerecipient HLA match at 8 alleles. Five of 258 CB units (2%) were RBC
replete. Assays enumerating cell populations and measuring post-thaw
viability have been previously described in detail [11,12]. Viability was
measured using ﬂow cytometric evaluation of 7-amino-actinomycin D
staining (Beckman Coulter, Brea, CA). Post-thaw viable TNC dose was
calculated as follows: TNC count  CD45þ cell viability divided by patient
weight. Nonviable TNC dose was calculated as the total TNC dose minus the
viable TNC dose. Most units underwent albumin-dextran dilution; however,
for the 35 that were washed (14%), the infused cell doses, including the
infused viable CD34þ cell dose and the percentage of viable CD34þ cells,
were determined postwash.Post-Transplantation Donor Chimerism
Donor chimerism was determined in the bone marrow at day 21 post-
transplantation and in blood at day 28 and at subsequent serial time
points in blood and bone marrow [3]. The dominant CB unit was either the
only 1 detected or the 1 that predominated on subsequent serial testing at
days 21, 28, 60, 100, 180, and 365 post-transplantation. A dominant unit
could be assigned based on bone marrow chimerism analysis even in pa-
tients with clinical graft failure.Table 1
Characteristics of 129 Recipients of Myeloablative dCBT
Characteristics Value
Median age, yr (range) 35 (.9-69)
Children < 16 yr 31 (24%)
Median weight, kg (range) 68 (8-116)
Diagnosis
AML 61 (47%)
ALL 33 (26%)
MDS/MPD 10 (8%)
NHL/CLL/HL 25 (19%)
CMV serostatus of recipient
Negative 59 (46%)
Positive 70 (54%)
Myeloablative conditioning type
High dose 65 (50%)
Intermediate intensity 64 (50%)
AML indicates acute myeloid leukemia; ALL, acute lymphoblastic leukemia;
MDS, myelodysplastic syndrome; MPD, myeloproliferative disorder; NHL,
non-Hodgkin lymphoma; CLL, chronic lymphocytic leukemia; HL, Hodgkin
lymphoma; CMV, cytomegalovirus.Statistical Analysis
The day of neutrophil recovery was deﬁned as the ﬁrst of 3 consecutive
days with a sustained neutrophil count .5  109/L. The cumulative inci-
dence of neutrophil engraftment was calculated with death before this
endpoint as the competing risk. Variables evaluated for their association
with engraftment were dominant and nondominant unit HLA-A, -B, -C, and
-DRB1 allele match to the patient, and post-thaw infused viable cell doses
(including TNC, CD34þ cells, CD3þ cells, CD3-16þ56þ cells analyzed as
continuous variables), and the percentage of viable CD45þ, CD3þ, and CD34þ
cells post-thaw. The association between neutrophil engraftment and unit
viable and nonviable TNC doses was also analyzed. A dominant unit CD34þ
cell dose cutpoint of 1.20 105/kg was chosen for subgroup analysis because
this separated the third of patients with highest dominant unit CD34þ cell
dose from the two thirds with the lowest doses.
Patient diagnosis, cytomegalovirus serostatus, and conditioning
regimen intensity were not analyzed because they were not associated with
neutrophil engraftment in a previous analysis of this study population [12].
Univariate and multivariate associations were assessed using cause-speciﬁc
Cox proportional hazards regression. All variables that reached P  .05 on
univariate analysis were included in the multivariate model. Analysis was
performed using IBM SPSS Statistics, version 21 (Chicago, IL).RESULTS
Neutrophil Engraftment and Unit Dominance
Table 1 describes the study patients. Approximately one
fourth were children. The graft characteristics by unit
dominance are shown in Table 2. Only 31 patients (24%)
received units that each had an infused TNC dose2.5107/
kg, whereas 47 (36%) were given 2 units each having an
infused TNC dose <2.5 107/kg. The cumulative incidence of
neutrophil engraftment at day 45 post-transplantation was
95% (95% conﬁdence interval [CI], 90% to 98%) with a median
time to engraftment of 24 days (range,12 to 43). Only a single
(dominant) unit was detected post-transplantation in 111
patients (86%) at 21 to 28 days. The nondominant unit was
detected in the other 18 patients (14%) at 21 to 28 days post-
transplant, with a median contribution of 20% (range, 6% to
48%). The detection of the nondominant unit at days 21 to 28
was not associated with any engraftment advantage: The
median neutrophil recovery was 27 days (range, 14 to 34) in
patients in whom both units were detected versus 24 days
(range, 12 to 43) for those with hematopoiesis detected from
only a single unit.
Associations between Dominant and Nondominant Unit
Characteristics and Neutrophil Engraftment
In univariate analyses, dominant unit infused viable cell
doses (TNC, CD34þ, CD3þ, and CD3-56þ16þ) and the per-
centage of viable CD34þ cells post-thaw (CD34þ cell
viability) were all signiﬁcantly associated with the speed and
success of neutrophil engraftment (Table 3). Infused viable
TNC and CD3þ cell doses of the nondominant unit were also
associated with the speed and success of engraftment
(Table 3). Donorerecipient HLA match of the dominant and
nondominant units was not associated with the time to
neutrophil engraftment or the uniteunit HLA match. In
multivariate analysis, the dominant unit infused viable
CD34þ cell dose, the percentage of viable CD34þ cells in the
dominant unit, and the nondominant unit infused TNC dose
were independently associatedwith the speed and success of
neutrophil engraftment (Table 3).
To investigate the effects of the nondominant unit TNC
dose further, we analyzed the subset of patients in whom
only the dominant unit was detected post-transplant.
Among these 111 patients, the nondominant unit TNC dose
remained independently associated with engraftment in
multivariate analysis (hazard ratio [HR], 1.44; 95% CI, 1.06 to
Table 2
Characteristics of 258 CB Units According to Unit Dominance
Characteristics Value
Median infused TNC  107/kg (range)
Dominant unit 2.18 (.91-12.79)
Nondominant unit 2.47 (1.13-8.31)
Median infused viable CD34þ cells  105/kg (range)
Dominant unit .92 (.08-4.77)
Nondominant unit .90 (.15-6.42)
Median infused viable CD3þ cells  106/kg (range)
Dominant unit 4.27 (.80-15.30)
Nondominant unit 3.68 (.32-12.00)
Median infused viable CD3-CD56/16þ cells 106/kg
(range)
Dominant unit 3.12 (.28-16.88)
Nondominant unit 3.37 (.61-14.97)
Median infused CD34þ cell viability, % (range)
Dominant unit 93 (53-98)
Nondominant unit 91 (34-99)
Median infused CD3þ cell viability, % (range)
Dominant unit 89 (37-97)
Nondominant unit 87 (13-98)
Median infused CD45þ cell viability, % (range)
Dominant unit 46 (21-87)
Nondominant unit 41 (9-69)
HLA-A, -B, -C, -DRB1 allele match
Dominant uniterecipient
2-5/8 84 (65%)
6-8/8 45 (35%)
Nondominant uniterecipient
2-5/8 94 (73%)
6-8/8 35 (27%)
Uniteunit
2-5/8 100 (78%)
6-8/8 29 (22%)
Figure 1. Cumulative incidence of neutrophil engraftment according to the
infused viable TNC dose (  107/kg) of the nondominant unit in patients with a
dominant unit CD34þ cell dose <1.20  105/kg (n ¼ 86).
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unit TNC dose effect would be seen primarily in patients
whose dominant unit had a relatively low infused viable
CD34þ cell dose. Indeed, the nondominant unit TNC dose
association with the speed and success of neutrophil
engraftment was only evident in two thirds of patients
(n¼ 86) whose dominant unit infused viable CD34þ cell dose
was <1.20  105/kg (HR, 1.39; 95% CI, 1.06 to 1.83; P ¼ .006;
Figure 1). There was no association in patients whoseTable 3
Analysis of Associations between Neutrophil Engraftment and Infused CB Unit Cha
Variable Univariate Analysis
HR 95% CI
Dominant unit
Total TNC  107/kg 1.28 1.17-1.41
Viable CD34þ  105/kg 1.89 1.59-2.45
Viable CD3þ  106/kg 1.09 1.03-1.16
Viable CD3-CD56/16þ  106/kg 1.14 1.06-1.22
CD34þ viability (%) 1.31 1.05-1.65
CD3þ viability (%) 1.17 .99-1.37
CD45þ viability (%) 1.12 .98-1.28
Nondominant unit
Total TNC  107/kg 1.35 1.18-1.54
Viable CD34þ  105/kg 1.18 .97-1.43
Viable CD3þ  106/kg 1.16 1.07-1.25
Viable CD3-CD56/16þ  106/kg 1.06 .98-1.15
CD34þ viability (%) .95 .81-1.12
CD3þ viability (%) 1.00 .91-1.10
CD45þ viability (%) .92 .79-1.07
Dominant uniterecipient HLA match* 1.05 .73-1.52
Nondominant uniterecipient HLA match* .94 .63-1.39
Uniteunit HLA match* .95 .62-1.46
* Reﬂects HLA-A, -B, -C, -DRB1 allele match; 2-5/8 versus 6-8/8.dominant unit had a higher infused viable CD34þ cell dose
(HR, 1.03; P ¼ .799).Analysis of the Association between Nondominant Unit
Viable and Nonviable TNC Doses and Neutrophil
Engraftment
Having determined that the nondominant unit TNC dose,
but not its CD34þ or CD3þ cell doses, was associatedwith time
to neutrophil engraftment, we investigated the association
between the viable and nonviable TNC doses of the nondomi-
nant unit and engraftment. In univariate analyses, both higher
viable and nonviable TNC doses of the nondominant unitwere
signiﬁcantly associated with improved neutrophil engraft-
ment. Inmultivariate analysis, however, only higher nonviable
TNC dose of the nondominant unit was independently associ-
atedwith improved engraftment (HR,1.52; 95% CI,1.13 to 2.04;
P ¼ .006), along with higher dominant unit viable CD34þ cell
dose and a higher percentage of viable CD34þ cells in the
dominant unit (HR, 1.78; 95% CI, 1.30 to 2.43; P < .001 and HR,
1.34; 95% CI, 1.02 to 1.77; P ¼ .037, respectively).racteristics
Multivariate Analysis
P HR 95% CI P
<.001 .94 .72-1.21 .622
<.001 1.86 1.39-2.49 <.001
.004 .96 .88-1.05 .327
<.001 1.03 .93-1.14 .615
.017 1.36 1.04-1.78 .026
.063
.105
<.001 1.34 1.04-1.72 .026
.107
<.001 .96 .85-1.09 .521
.159
.517
.953
.292
.786
.745
.831
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This analysis of myeloablative dCBT reveals 2 important
ﬁndings relevant to the practice of dCBT. First, the detection
of the nondominant unit at days 21 to 28 was not associated
with any engraftment advantage. Of even greater interest
was that a higher nondominant unit TNC dose was inde-
pendently associated with improved neutrophil engraft-
ment after dCBT when the infused viable dominant unit
CD34þ cell dose was low. This was true even when the unit
itself was not detected after transplantation. This observa-
tion suggests that despite their lack of engraftment,
nondominant units can facilitate engraftment of low dose
dominant units in myeloablative dCBT recipients. Our ﬁnd-
ings are in contrast to those of the recently published BMT
CTN 0501 [6], in which no engraftment advantage was
observed for children and adolescents randomized to
receive double-unit rather than single-unit CBT. However,
all patients in BMT CTN 0501 received at least 1 unit with
TNC dose >2.5  107/kg, whereas in our study only 64%
received at least 1 unit with TNC >2.5  107/kg. Thus, the
lack of beneﬁt in pediatric dCBT likely reﬂects the relatively
high cell doses available to the pediatric patients in the BMT
CTN trial.
The actual mechanism by which the nondominant unit
facilitates engraftment of the dominant unit remains unclear.
Given there was no advantage associated with initial coen-
graftment of both units, any effect of the nondominant unit is
not explained by direct contribution to donor hematopoiesis,
even transiently. The murine model of Eldjerou et al. [16]
using aliquots of each unit from a clinical dCBT demon-
strated that unit dominance was mediated by CD34 cells,
but the kinetics of engraftment were not examined. How-
ever, in a murine model, Scaradavou et al. [17] reported that
combined transplantation of suboptimal doses of neonatal
blood (the murine equivalent of CB) from 2 donors acted
synergistically to enhance recipient survival post-transplant,
even though 1 of the 2 donors did not contribute signiﬁcantly
to hematologic reconstitution.
Paradoxically, the association between higher nondomi-
nant unit TNC dose and improved engraftment in the current
study was related to the nonviable TNC component rather
than the viable TNC dose. Enhanced CB engraftment has been
observed in the presence of irradiated third-party cells in a
murine model, although the mechanism by which the irra-
diated cells enhanced engraftment was not determined [18].
Overall, although the mechanism of a possible facilitation
effect is not explained, our data are of great clinical signiﬁ-
cance. They suggest the presence of the nonengrafting unit
can foster the engraftment of a low dosed dominant unit and
may explain, at least in part, why our series is associatedwith
relatively high rates of neutrophil engraftment despite the
low cell doses of the engrafting units.
Our ﬁndings are provocative and require conﬁrmation.
In the interim, and most importantly, from a clinical
standpoint our ﬁndings support the practice of dCBT in
adults and larger children in whom the best available
single unit has a low CD34þ cell dose. The continued
investigation of dCBT biology is also of great interest to the
transplant ﬁeld.ACKNOWLEDGMENTS
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